Loading...
Uploaded by ElsGlobalMedicalNews on Jun 11, 2010
Alemtuzumab may benefit MS patients who experienced autoimmune adverse events. Most remain disease free in 4-year follow-up, Dr. Vesna Brinar tells GMNN's Heidi Splete.
News & Politics
Standard YouTube License
Load more suggestions
Link to this comment:
All Comments (0)